Humanwell Healthcare: controller's fund occupation, CSRC probe and a December 2025 penalty
Humanwell Healthcare: controller's fund occupation, CSRC probe and a December 2025 penalty: a public-record watch file compiled by Falling Shares Intelligence from filings and exchange disclosures, as of 2026-11-09. In 2023 the Shanghai Stock Exchange sanctioned the then controlling shareholder over non-operating use of the company's funds; Yicai reported that the CSRC opened a probe into its actual controller in August 2023.
From a 2023 exchange sanction over funds taken by its controlling shareholder to a December 2025 penalty notice and a change of control to a state group: what the record shows.
Falling Shares Intelligence, Edited by Wung Thomas, Editor-in-Chief. As of .
Summary
- In 2023 the Shanghai Stock Exchange sanctioned the then controlling shareholder over non-operating use of the company's funds; Yicai reported that the CSRC opened a probe into its actual controller in August 2023.
- Hubei securities authorities fined Humanwell and others RMB36.7m in total in December 2025, according to Caixin, over undisclosed transfers of up to RMB12.8bn to its former parent and other violations.
- Humanwell received an ST risk label on 16 December 2025; control had passed to a China Merchants Group unit in July 2025.
- The company said in 2023 that its operations were not significantly affected.
Key figures
| Penalty notice, Dec 2025 | RMB36.7m (Total on Humanwell, its former parent and executives, per Caixin) |
|---|---|
| Funds alleged taken by former parent | RMB12.8-12.9bn (Two Caixin articles give 12.9bn (2019-2022) and up to 12.8bn) |
| China Merchants investment in restructuring | RMB11.8bn (Court-approved plan; control passed 30 Jul 2025) |
Fund occupation and early action
Exchange sanctions controller over fund occupation
Yicai reported that the Shanghai Stock Exchange barred the actual controller from senior management of a listed company for three years in February 2023 over disclosure violations, and described the controlling shareholder's borrowing of company funds through third-party agencies as non-operating capital occupation by related parties. (Feb 2023)
CSRC opens probe into the actual controller
Yicai reported on 8 August 2023 that the China Securities Regulatory Commission (CSRC) was investigating the actual controller for allegedly failing to disclose required information. It said the controlling shareholder borrowed RMB12.9bn from Humanwell through third-party agencies between 2019 and 2022, and that about 86.5% of the shareholder's stake was pledged. (Aug 2023)
The 2025 CSRC cases
Second CSRC notice to the former parent
Caixin reported that Dangdai Group, Humanwell's former controlling shareholder, said it received a CSRC notice on 28 November 2025 over suspected disclosure violations and illegal financing, its second CSRC case. Caixin said the CSRC's decisions could delay the group's restructuring plan. (28 Nov 2025)
Penalty notice disclosed
Caixin reported that Humanwell disclosed a penalty notice from Hubei securities authorities, fining Humanwell, its former parent and several executives RMB36.7m in total, with the former parent separately fined RMB9m. The conduct, under the former parent's control, included funnelling up to RMB12.8bn to the parent through undisclosed transactions, a RMB1.7bn property purchase from a closely tied company not disclosed as a related-party deal, concealment of a stake purchase, and overstating net profit by over RMB300m by mid-2022. (14 Dec 2025)
ST risk label applied
Caixin reported that Humanwell's shares received an ST (special treatment) label on 16 December 2025, limiting daily moves to 5%. (16 Dec 2025)
Company response and change of control
Company says operations not significantly affected
Humanwell said its directors and senior management continued their regular duties and that the probe would not have a significant impact on operations, per Yicai. (Aug 2023)
Court-approved restructuring and new state controller
A Wuhan court approved a restructuring plan under which China Merchants Innovation Technology would invest RMB11.8bn and gain control of Humanwell, per Caixin. A company announcement of 31 July 2025, via an aggregator, said the controlling shareholder changed to China Merchants Life Science (Wuhan), effective 30 July 2025, with China Merchants Group as de facto controller. (Apr - Jul 2025)
Standard
This file compiles regulator and exchange actions, company filings and published reporting about Humanwell Healthcare (Group) Co., Ltd.. Allegations are attributed to those who made them. An investigation is not a charge, a charge is not a finding, and nothing here is a finding of wrongdoing unless a competent authority has made one. Here, Chinese securities authorities are reported to have made penalty findings relating to conduct under the company's former controlling shareholder; the company has since passed to state control and says it has corrected the matters. No criminal referral relating to the company was found. Individuals are not named unless an official document names them and they are central; otherwise roles are used. This is news coverage for information only, not investment advice.
Right of reply
Humanwell Healthcare (Group) Co., Ltd., and anyone named in a record cited here, can send corrections or comments to info@fallingshares.com (or directly to the Editor-in-Chief, Wung Thomas, at wungthomas@fallingshares.com). Material responses will be published alongside the relevant entry.